国际内分泌代谢杂志2024,Vol.44Issue(4) :246-249,278.DOI:10.3760/cma.j.cn121383-20230828-08066

垂体癌诊断与治疗的研究进展

Research progress in the diagnosis and treatment of pituitary carcinoma

董文静 颜世举 赵健 谷伟军
国际内分泌代谢杂志2024,Vol.44Issue(4) :246-249,278.DOI:10.3760/cma.j.cn121383-20230828-08066

垂体癌诊断与治疗的研究进展

Research progress in the diagnosis and treatment of pituitary carcinoma

董文静 1颜世举 2赵健 1谷伟军3
扫码查看

作者信息

  • 1. 解放军医学院,北京 100039
  • 2. 解放军总医院海南医院骨科,三亚 572013
  • 3. 解放军总医院第一医学中心内分泌科,北京 100853
  • 折叠

摘要

垂体癌(pituitary carcinoma)是一种较为罕见的侵袭性恶性肿瘤,可浸润邻近组织,包括海绵窦、骨、蝶窦等,且常规治疗无效.在没有恶性肿瘤组织学特征的情况下,只有出现脑、脊髓或全身转移时,才能证实垂体癌的存在.其生长快速、频繁复发、诊断延迟滞后、常规治疗效果不佳以及预后差等特点,使垂体癌的综合管理与治疗十分困难.本文通过对垂体癌诊治的最新研究进展进行综述,加强临床医生对该病的认识,尽可能提高患者的长期生存率.

Abstract

Pituitary carcinoma(PC)is a rare invasive malignant tumor,which can invade adjacent tissues,including cavernous sinus,bone,sphenoid sinus,etc.,and it is ineffective to conventional treat-ment.Without histological features of malignant tumors,PC could be confirmed only when cerebrospinal or systemic metastases were present.Moreover,the characteristics of rapid growth,frequent recurrence,de-layed diagnosis,poor response to conventional treatment,and poor prognosis make it difficult to manage and treat synthetically.This article reviewed the latest progress in the diagnosis and treatment of pituitary carci-noma,so as to strengthen the clinicians'knowledge of the disease and improve the long-term survival rate of patients as much as possible.

关键词

垂体癌/替莫唑胺/靶向治疗/肽受体放射性核素治疗

Key words

Pituitary carcinoma/Temozolomide/Targeted therapy/Peptide receptor radionuclide therapy

引用本文复制引用

基金项目

北京市自然科学基金面上基金项目(7232155)

出版年

2024
国际内分泌代谢杂志
中华医学会,天津医科大学

国际内分泌代谢杂志

CSTPCD
影响因子:0.842
ISSN:1673-4157
参考文献量2
段落导航相关论文